The disease primarily affects middle-aged women and has a poor long-term prognosis despite therapeutic advances.

CyPath® Lung detected a Stage 1A neuroendocrine tumor in a patient's lung when imaging and other adjuvant tools could not.

BiomX has dosed the first subject in the randomised Phase IIb trial of the company’s fixed multi-phage therapy, BX004, to ...

Backed by an initial funding of $15 million from the National Science Foundation, the Regenerative Medicine Engine is the ...

Viatris Inc. (NASDAQ: VTRS) is one of the best low priced pharma stocks to buy now. On June 27, Viatris received approval ...

Insmed stock is soaring as it approaches the potential approval of its second drug. CEO Will Lewis calls it a "skeleton key." ...

First patient dosing in Company’s Phase 2b trial marks pivotal milestone in phage therapy development program targeting ...

There are many things we’ve learned from studying the ancient Egyptians. One especially fascinating discovery was evidence of skeletal deformities in mummies, which serves as silent markers of a ...

Three young Triangle-based medical technology companies with roots in Duke University research labs are getting major global attention from their industry. They’re among the 65 cutting-edge companies ...

There is no clear FDA framework for inhalable biologics. Each product is evaluated case-by-case. That’s bureaucratic speak ...

Digital inhalers can detect significant changes in physiologic and inhaler use metrics in the 14 days before COPD exacerbations.